Document is current
Any future updates will be listed below
-
Authors
Jacobi, David
Artime, Esther
Bertrand, Marine
Kayali, Aya
Adam, Atif
Lampropoulou, Anastasia
-
Funding
Funding for this research was provided by:
Eli Lilly and Company
- License Information
-
More Information
Article History
Received: 2 October 2025
Accepted: 27 March 2026
First Online: 22 April 2026
Declarations
:
: Esther Artime, Marine Bertrand and Aya Kayali are employees and minor shareholders of Eli Lilly and Company. Anastasia Lampropoulou is a former employee and a former minor shareholder of Eli Lilly and Company. David Jacobi has received consulting fees from Eli Lilly and Company, Novo Nordisk and Fitforme, payment or honoraria from Eli Lilly and Company, Novo Nordisk and Amgen and received travel reimbursement from Eli Lilly and Company and Novo Nordisk. Atif Adam has no conflicts of interest to declare.
: All analyses performed in this study were conducted in accordance with Data Use Agreement terms as specified by the data owners. Reference made to the France LPD is intended to be descriptive of the data asset licensed by IQVIA. For the France database, there was no institutional review board applicable to the usage and dissemination of the results of this study or required registration of the protocol with additional ethics oversight. This study was performed in accordance with the Helsinki Declaration of 1964 and its later amendments.
